Upgrades Neutral Buy X

MLTX MoonLake Immunotherapeutics

Goldman

$62 $82

Resumed Outperform X

MLTX MoonLake Immunotherapeutics

Wedbush

$92 $73

Initiated Outperform X

MLTX MoonLake Immunotherapeutics

Oppenheimer

$104

Initiated Neutral X

MLTX MoonLake Immunotherapeutics

Goldman

$62

Initiated Outperform X

MLTX MoonLake Immunotherapeutics

Wolfe Research

$77

Initiated Buy X

MLTX MoonLake Immunotherapeutics

Citigroup

$72

Initiated Buy X

MLTX MoonLake Immunotherapeutics

Stifel

$74

Downgrades Buy Neutral X

MLTX MoonLake Immunotherapeutics

Bryan Garnier

Initiated Buy X

MLTX MoonLake Immunotherapeutics

Needham

$76

Initiated Equal Weight X

MLTX MoonLake Immunotherapeutics

Barclays

$28

Initiated Buy X

MLTX MoonLake Immunotherapeutics

Guggenheim

$51

Initiated Outperform X

MLTX MoonLake Immunotherapeutics

Wedbush

$33

Initiated Buy X

MLTX MoonLake Immunotherapeutics

BTIG Research

$36

Initiated Overweight X

MLTX MoonLake Immunotherapeutics

Cantor Fitzgerald

$23

Initiated Buy X

MLTX MoonLake Immunotherapeutics

Bryan Garnier

$22

Initiated Buy X

MLTX MoonLake Immunotherapeutics

Jefferies

$16

Initiated Outperform X

MLTX MoonLake Immunotherapeutics

SVB Leerink

$17

Initiated Outperform X

MLTX MoonLake Immunotherapeutics

Cowen

MLTX  MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.